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Background: Patients with critical limb ischemia (CLI) have a high rate of adverse cardiovascular events, particularly when
undergoing surgery. We sought to determine the effect of surgery and vascular disease on platelet and monocyte
activation in vivo in patients with CLI.
Methods: An observational, cross-sectional study was performed at a tertiary referral hospital in the southeast of Scotland.
Platelet and monocyte activation were measured in whole blood in patients with CLI scheduled for infrainguinal bypass
and compared with matched healthy controls, patients with chronic intermittent claudication, patients with acute
myocardial infarction, and those undergoing arthroplasty (n  30 per group). Platelet and monocyte activation were
quantified using flow cytometric assessment of platelet-monocyte aggregation, platelet P-selectin expression, platelet-
derived microparticles, and monocyte CD40 and CD11b expression.
Results: Compared with those with intermittent claudication, subjects with CLI had increased platelet-monocyte
aggregates (41.7% 12.2% vs 32.6% 8.5%, respectively), platelet microparticles (178.7 106.9 vs 116.9 53.4), and
monocyte CD40 expression (70.0%  12.2% vs 52.4%  15.2%; P < .001 for all). Indeed, these levels were equivalent
(P-selectin, 4.4% 2.0% vs 4.9% 2.2%; P> .05) or higher (platelet-monocyte aggregation, 41.7% 12.2% vs 33.6%
7.0%; P < .05; platelet microparticles, 178.7  106.9 vs 114.4  55.0/L; P < .05) than in patients with acute
myocardial infarction. All platelet and monocyte activation markers remained elevated throughout the perioperative
period in patients with CLI (P < .01) but not those undergoing arthroplasty.
Conclusions: Patients undergoing surgery for CLI have the highest level of in vivo platelet and monocyte activation, and
these persist throughout the perioperative period. Additional antiplatelet therapy may be of benefit in protecting vascular
patients with more severe disease during this period of increased risk. (J Vasc Surg 2010;52:697-703.)
Clinical Relevance: Peripheral arterial disease is increasingly common and is associated with a significant risk of
cardiovascular complications, especially at the time of surgery. Despite this, patients are poorly provided with evidence-
based therapies such as antiplatelet and lipid-lowering medications. Platelets play a key role in the pathogenesis of
atherothrombosis, with elevated levels of in vivo platelet activation prognostic of adverse clinical events. This study
demonstrates, for the first time to our knowledge, significantly greater levels of platelet activation in patients with severe
peripheral arterial disease compared with patients with acute myocardial infarction or patients undergoing other
moderate- to high-risk surgical procedures. This further emphasizes the need for improved risk stratification and
cardioprotection of this vulnerable group.Patients with peripheral arterial disease (PAD) are at in-
creased risk of adverse cardiovascular events.1 This risk in-
creaseswith the severity of disease,with progressive reductions
in the ankle brachial pressure index (ABPI) being an indepen-
dent predictor of cardiovascular outcome.2,3 Cardiovascular
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doi:10.1016/j.jvs.2010.04.024risk factor management is therefore the first-line treatment of
patients with PAD. These patients are particularly at risk
during the perioperative period.Myocardial infarction (MI) is
the commonest life-threatening complication of major vascu-
lar surgery, with a reported perioperative incidence of 8% to
40%, depending on the diagnostic criteria.4-6 This is compa-
rable to the 30-day death and reinfarction rate of 8% to 20%
seen in patients with acute coronary syndromes.7 Despite this,
patients with PADoften fail to receive evidence-basedmedical
therapies. There is clearly an unmet need for improved risk
stratification of these patients with appropriately tailored in-
tensive medical regimens.
Atherogenesis and its complications are complex
processes involving inflammatory and thrombotic mecha-
nisms.8-10Monocyte adhesion to a damaged endothelium is a
central step in the initiation and progression of atherosclerosis
and appears to play a key role in plaque destabilization. In
contrast, platelets can adhere to atherosclerotic lesions in the
presence or absence of an overlying endothelium8 and contrib-
ute to thrombus formation that is responsible for acute cardio-
vascular events. Hence, platelet and monocyte activation both
predispose to plaque growth, instability, and rupture.
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platelet-monocyte aggregates that promote expression of
vascular cell adhesion molecules and increase leucocyte
adhesion to the inflamed endothelium.11 In addition, the
CD40/CD40 ligand dyad, which is expressed on the sur-
face of activated monocytes and platelets, is a major inflam-
matory trigger that promotes release of inflammatory cyto-
kines, adhesion molecules, and procoagulant activity.12
Disruption of CD40/CD40L or platelet-monocyte aggre-
gation leads to the retardation of atherosclerotic lesions in
animal studies.13,14
Raised levels of platelet-monocyte aggregates and
monocyte CD40 have been detected in smokers, patients
with diabetes mellitus, acute coronary syndromes, and in
those at risk of rethrombosis after percutaneous coronary
interventions.15-18 They are surrogate markers of clinical
risk and are predictive of adverse cardiac events. Several
studies have assessed platelet activation in peripheral ath-
erosclerosis and demonstrated a progressive increase in
activation with increasing severity of disease.19-21 How-
ever, there have been relatively few reports of platelet
activation and cellular inflammation at the time of opera-
tion,22-24 and none, to our knowledge, have compared
PAD patients with other high-risk populations.
We wished to investigate platelet and monocyte activa-
tion in patients with PAD specifically at the time of surgery
and compare this to levels of activation in other high-risk
populations. The high incidence of perioperative adverse
cardiovascular events in patients with severe PAD could be
mediated by increased systemic inflammation and platelet
Table I. Inclusion and exclusion criteria
Healthy volunteers Claudicants
Inclusion criteria Age 50 y Age 50 y
Intermittent claudicat
ABPI 1 and 0.2
Rutherford- Baker II,
Exclusion
criteria
PAD Dual antiplatelet thera
IHD, CVD Warfarin
Smoking
Hypertension
Diabetes
Lipid-lowering
agents
Antiplatelet therapy
Antihypertensive
agents
Warfarin
ABPI, Ankle-brachial pressure index; CVD, cerebrovascular disease; ECG, eactivation. These patients may potentially benefit from riskstratification and appropriately tailored medical regimens,
as occurs in patients with coronary atherosclerotic disease.
This exploratory study may support the conduct of inter-
ventional projects aimed at reducing surrogate markers of
clinical risk, before clinical trials of intensive antiplatelet and
anti-inflammatory strategies.
METHODS
This observational, cross-sectional study was per-
formed with the approval of the local ethics committee and
in accordance with the Declaration of Helsinki. All partic-
ipants provided written informed consent.
Participants. Participants were recruited from five
groups (n  30 per group): (1) patients with nonthrom-
boembolic CLI, (2) patients with chronic intermittent
claudication, (3) patients with a non-ST segment elevation
MI, (4) otherwise healthy patients undergoing hip or knee
arthroplasty, and (5) healthy volunteers. The inclusion and
exclusion criteria are summarized in Table I.
Patients with CLI, defined by the presence of rest pain
or skin ulceration, or both, and an ABPI 0.2, who were
scheduled to undergo infrainguinal bypass or amputation
were recruited from the surgical vascular unit. Patients who
had symptoms of intermittent claudication with an ABPI of
1 and0.2, were recruited from the outpatient claudica-
tion clinic.
The 60 PAD patients received maintenance aspirin (75
mg daily) and statin therapy for at least 6 weeks before
inclusion. We wished to examine platelet activation under
the standard medical regimen; therefore, patients receiving
Critical limb ischemia
Non-ST elevation
MI Arthroplasty
Age 50 y Age 50 y Age 50 y
Rest pain and/or skin
ulceration or
necrosis
Cardiac chest pain
plus ECG
changes plus
plasma
troponin I 
0.2 g/L
ABPI  0.2
Rutherford-Baker
IV-VI
Dual antiplatelet
therapy
PAD PAD
Warfarin IHD, CVD
Smoking
Hypertension
Diabetes
Lipid-lowering
agents
Antiplatelet
therapy
Antihypertensive
agents
Warfarin
cardiogram; IHD, ischemic heart disease; MI, myocardial infarction.ion
III
pyclopidogrel or warfarin were excluded. At present, the only
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PAD is coexisting history of recent (6 months) coronary
artery stenting or stroke.
Patients presenting to the coronary care unit and diag-
nosed with a non-ST elevation MI, defined as chest pain
with electrocardiographic (ECG) changes and elevated
plasma troponin I concentration (0.2 g/L), were re-
cruited.
We wished to examine the contribution of surgical
stress (without underlying PAD) to in vivo platelet activa-
tion. After discussion with a panel of consultant vascular
surgeons and anesthetists, we concluded knee or hip ar-
throplasty represented surgery of a similar magnitude to
peripheral bypass or amputation and was likely to be per-
formed in patients of a comparable age. Patients aged50
years undergoing elective arthroplasty were approached.
To limit the effect of atherosclerosis on platelet activation,
we excluded patients with a history of diabetes, hyperten-
sion, ischemic heart disease or stroke, smoking, or anti-
platelet, antihypertensive, or statin use. Patients undergo-
ing arthroplasty did not receive perioperative heparin
according to the unit policy.
Sequential healthy individuals aged 50 were re-
cruited.
Blood sampling. Single baseline samples were taken
from all 150 participants. In patients with non-ST segment
elevation MI, samples were taken 24 hours of hospital-
ization and after the initiation of dual antiplatelet medica-
tion with aspirin and clopidogrel. To compare periopera-
tive platelet and monocyte activation, three blood samples
were taken from patients undergoing vascular or orthope-
dic surgery preoperatively, immediately postoperatively,
and on the day after the operation.
Blood was drawn by venipuncture of a large antecubital
vein using a 19-gauge needle. Care was taken to ensure a
smooth blood draw without venous stasis. Samples were
processed immediately. Blood for assessment of platelet-
monocyte aggregates, platelet expression of P-selectin, and
monocyte CD40 and CD11b, was collected into tubes
containing the direct thrombin inhibitor, D-phenylalanyl-
L-propyl-L-arginine chloromethyl ketone (PPACK, Cam-
bridge Biosciences, Cambridge, UK). Blood for the assess-
ment of platelet microparticles was collected into sodium
citrate. Platelet-poor plasma was prepared by centrifuga-
tion at 2000g at 4°C for 10 minutes and confirmed by a
platelet count of 107/L.
Assessment of in vivo platelet activation. Flow
cytometric measurements of platelet-monocyte aggregates
and platelet surface expression of P-selectin were performed
as described previously.15,16 Immunolabeling was per-
formed in whole blood 5 minutes of collection. Directly
conjugated monoclonal antibodies were obtained from
DakoCytomation (Cambridge, UK) and Serotec (Ox-
ford, UK). To assess platelet-monocyte aggregates, 60
L of blood were incubated for 15 minutes with a
fluorescein isothiocyanate (FITC)-conjugated anti-
CD42a monoclonal antibody (platelet marker) and aphycoerythrin (PE)-conjugated anti-CD14 monoclonal
antibody (monocyte marker) before fixation and eryth-
rocyte lysis with 500 L of FACSLyse solution (Becton
Dickinson, Oxfordshire, United Kingdom).17
Cells were measured by flow cytometry (EPICS XL2;
Beckman-Coulter). Samples were analysed with EXPO
32 software (Cytometry Systems). Platelet-monocyte ag-
gregates were detected by gating for cells that were
positive for both CD14 PE and CD42a FITC. Platelet
surface expression of P-selectin was assessed by gating for
cells that were positive for both FITC-conjugated anti-
CD42a monoclonal antibody, (platelet marker) and PE-
conjugated anti-CD62P monoclonal antibody (throm-
bin receptor-activating peptide [TRAP 1], immunoglobulin
G1). Isotype controls were used to reduce error from nonspe-
cific binding.
Platelet microparticles were identified by both size and
expression of platelet markers CD41 (glycoprotein [GP]
IIb) and CD31 (GPIIIa; platelet endothelial cell adhesion
molecule-1). Aliquots (25 L) of platelet-poor plasma
were incubated for 30 minutes with a PE-conjugated anti-
CD31 monoclonal antibody and a FITC-conjugated anti-
CD41monoclonal antibody (Serotec, Oxford, UK), before
dilution with phosphate-buffered saline to form a volume
of 1 mL.
Platelet microparticles were gated according to their
size (events 1.0 m) by assessment of their forward light
scatter. TruCOUNT beads of 1.0 m (Becton Dickenson)
of a known concentration were used to calculate the vol-
ume of sample analyzed over 120 seconds at medium flow
rate. This allowed the absolute number of platelet micro-
particles to be measured. Isotype controls were used to
reduce error from nonspecific binding. Platelet micropar-
ticles were detected by gating for events that were sized1
m (based on forward scatter) and positive for both CD31
and CD41.
Assessment of in vivo monocyte activation. Monocyte
activation was assessed by flow cytometric measurement of
percentage of monocyte CD40 expression and mean fluo-
rescent intensity (MFI) of monocyte CD11b expression, as
described previously.15,16 Immunolabeling was performed
in whole blood within 5 minutes of collection. To evaluate
CD40 and CD11b on monocytes, blood was diluted 1:2
with phosphate-buffered saline and incubated with the
following monoclonal antibodies: anti-CD14:FITC (Sero-
tec), anti-CD40:PE (Serotec), anti-CD11b:PE (Serotec),
and appropriate isotype-matched controls for 20 minutes
before fixation and erythrocyte lysis with 500 L of
FACSLyse solution. Monocytes were identified by gating
for CD14-positive cells.
Statistical analysis. Data are shown as scatter plots or
mean standard deviation. Data were analyzed by analysis
of variance, 2 and Bonferroni post hoc tests, where appro-
priate, using Prism 4 software (GraphPad, La Jolla, Calif).
Statistical significance was taken as a two-sided value of P
.05.
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Participants were predominantly middle-aged men,
with groups having similar distribution of ages and no
significant difference in mean age (Table II). In keeping
with their clinical presentation, patients with peripheral
arterial and coronary heart disease had a range of cardiovas-
cular risk factors and medications that were not present in
the healthy volunteers or patients undergoing orthopedic
surgery (Table II). Of the 30 patients with CLI, 18 under-
went femoral-popliteal bypass and 12 underwent below
knee amputations. None underwent endovascular proce-
dures. Dry gangrene was present in 17, but none had wet
gangrene.
Baseline platelet activation. Platelet activation mark-
ers were lowest in healthy volunteers and patients sched-
uled for arthroplasty (Fig 1). Baseline platelet-monocyte
aggregation (41.7%  12.2%) and platelet microparticles
(178.7  106.9) were highest in patients with CLI com-
pared with all other groups (Fig 1). Although patients with
CLI had higher values of platelet P-selectin than healthy
volunteers or those undergoing arthroplasty (P  .001),
there was no demonstrable difference between these pa-
tients and those with claudication or non-ST elevation MI
(4.4% 2.0% vs 4.2% 2.0% and 4.9% 2.2% respectively;
P  .05; Fig 1).
Baseline monocyte activation. Monocyte activation
markers were lowest in healthy volunteers and patients
scheduled for arthroplasty (Fig 2). Baseline monocyte ex-
pression of CD40 (70%  12.2%) was highest in patients
with CLI compared with all other groups (Fig 2). Baseline
monocyte CD11b was greatest in patients with CLI com-
pared with all groups except those with claudication, where
it was equivalent (56.6 18.3 vs 50.5 13.9, respectively;
P  .05; Fig 2).
Perioperative platelet and monocyte activation.
Table II. Participant demographics
Variablea
Healthy volunteers Intermittent claudicati
(n  30) (n  30)
Mean  SD Mean  SD
Age, y a 59  3 60  4
No. (%) No. (%)
Male sex b 16 (53) 22 (73)
CV risk factors
Hypertension 0 18 (60)
Diabetes 0 7 (23)
CAD 0 10 (33)
Current smoker 0 17 (57)
Medications
Aspirin 0 30 (100)
Clopidogrel 0 0
Statin therapy 0 30 (100)
ACE inhibitor 0 3 (10)
-blocker 0 2 (6.7)
ACE, Angiotensin converting enzyme; CAD, coronary artery disease; CV,
aP  .38, one-way analysis of variance.
bP  .24, 2 analysis.Throughout the perioperative period, levels of all plateletand monocyte markers remained greater in patients with
CLI than in those undergoing arthroplasty (Fig 3 and 4;
P  .0001). Platelet and monocyte activation rose imme-
diately postoperatively in patients undergoing joint arthro-
plasty (P .05) before falling on the first postoperative day
(Fig 3 and 4). In contrast, platelet activation fell immedi-
ately after surgery in patients undergoing infrainguinal
revascularization or amputation (P  .05; Figure 3),
whereas monocyte activation remained unchanged (mono-
cyte CD40, P  .05) or rose on day 1 (monocyte CD11b;
P  .05; Fig 4).
There was no statistically significant difference in mark-
ers according to type of surgery performed for CLI (bypass
or amputation) and no difference in postoperative trend
(subanalysis not shown).
DISCUSSION
Consistent with previous studies,19-21 we have demon-
strated that platelet and monocyte activation is increased in
patients with PAD.We have shown for the first time, to our
knowledge, that patients undergoing surgery for CLI have
even greater levels of platelet and monocyte activation than
patients being treated for acute MI. In addition, perioper-
ative platelet andmonocyte activation is markedly increased
in these patients and exceeds the increase in platelet activa-
tion and inflammation attributable to surgery itself. This
study supports the need for an increased appreciation of the
cardiovascular risks associated with these patients and an
improvement in cardioprotective management, especially
in the perioperative period.
PAD affects nearly 30 million people in Western Eu-
rope and North America, and up to three-quarters of these
patients have coexistent coronary artery disease and a three-
fold increased risk of cardiovascular events and death.25
Despite attempts to raise awareness of PAD as an important
Critical limb ischemia Acute coronary syndromes Arthroplasty
(n  30) (n  30) (n  30)
Mean  SD Mean  SD Mean  SD
68  2 58  2 57  4
No. (%) No. (%) No. (%)
23 (77) 20 (67) 17 (57)
24 (80) 20 (67) 0
10 (33) 8 (27) 0
16 (53) 13 (43) 0
16 (53) 16 (53) 0
30 (100) 30 (100) 0
0 30 (100) 0
30 (100) 24 (80) 0
12 (40) 21 (70) 0
6 (20) 16 (53) 0
vascular.on
cardiomarker of cardiovascular risk, patients are often poorly
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and lipid-lowering medications.26-29 The reasons for this
are unclear, but appear to be related to a lack of awareness
amongst health professionals of the severity of the disease.
Our study demonstrated that patients with CLI have a
greater elevation in systemic markers of platelet and mono-
cyte activation than comparator groups. We acknowledge
that the healthy volunteers and patients undergoing arthro-
plasty did not receive antiplatelet agents or lipid-lowering
drugs, which can affect platelet activation. However, pa-
Fig 1. Scatter dot plots are shown for resting in vivo platelet
activation in healthy volunteers (HV, ), claudicants (), patients
with critical limb ischemia (CLI,’), patients with non-ST eleva-
tion myocardial infarction (NSTEMI,), and patients undergoing
arthroplasty (●). A, Percentage of platelet-monocyte aggregation.
B, Percentage of platelet P-selectin expression. C, Platelet-derived
microparticles (/mL). The horizontal lines represent population
means (n 30 per group). Analysis by one-way analysis of variance
with Bonferroni post-tests.tients with PAD have a high incidence of adverse cardio-vascular events despite existing medical therapy. Indeed,
the elevations in platelet activation were seen despite the
standard medical regimen of aspirin and statin therapy and
were even greater than those seen in patients with acuteMI.
It may be that there is scope for further management of
platelet activation in these patients.
Patients undergoing peripheral vascular surgery have a
particularly high incidence of perioperative cardiovascular
events. This has been attributed to increased platelet and
monocyte activity caused by the surgical process itself.
Patients without cardiovascular risk factors undergoing ar-
throplasty (and therefore no reason for elevated baseline
platelet activation) were recruited to assess the effect of
surgery alone on platelet activation. Our study showed that
throughout the perioperative period, platelet and mono-
cyte activation markers were higher in patients undergoing
vascular surgery than in those undergoing arthroplasty.
However, although platelet markers rose postoperatively in
Fig 2. Resting in vivo monocyte activation in healthy volunteers
(HV, ), claudicants (), patients with critical limb ischemia (CLI,
’), patients with non-ST elevationmyocardial infarction (NSTEMI,
), and patients undergoing arthroplasty (●). A, Percentage of
monocyte CD40 expression. B,Monocyte CD11b (mean fluores-
cent intensity, MFI). Horizontal lines represent population means
(n  30 per group). Analysis by one-way analysis of variance with
Bonferroni post-tests.patients undergoing arthroplasty, we were surprised to see
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those with CLI. Patients with PAD, especially CLI, have
high baseline levels of activated platelets and monocytes.
This is due to the underlying endothelial dysfunction and
tissue ischemia. We therefore propose that the lack of
response after surgery in these particular patients could be
due to the removal of thrombotic stimulus by amputation
or revascularization. These patients may benefit from in-
creased platelet inhibition before surgery.
Cardiovascular disease is a critical public health issue.
The prevalence of the disease and increased awareness of
the cost-benefit associated with the management of cardio-
vascular risk have led to the concept of potential screening
programs for vascular disease.30 In addition, recommenda-
Fig 3. Perioperative in vivo platelet activation is shown in patients
undergoing surgery for critical limb ischemia (’) and arthroplasty
(●). Platelet activation in patients undergoing infrainguinal
bypass or amputation was greater than in patients undergoing
arthroplasty throughout the perioperative period (P  .0001).
In vivo platelet activation measured by (A) percentage of platelet-
monocyte aggregation (P  .05) and (B) percentage of P-selectin
expression (P  .05), rose immediately postoperatively in patients
undergoing arthroplasty but fell in those with critical limb ischemia
(P  .001). Mean  standard deviation; analysis between patient
groups by two-way analysis of variance with repeated measures;
analysis between time points for the same patient group by one-
way analysis of variance with Bonferroni post-tests.tions are required for the most appropriate use of interven-tions and therapies for patients with different manifesta-
tions of PAD. The use of imaging technologies or
biomarkers could help risk-stratify patients and guide man-
agement. This study demonstrates that sensitive markers of
in vivo platelet and monocyte activation—known to be
predictors of clinical risk—are markedly elevated in patients
with severe PAD at the time of surgery, despite current
medical therapy. This is in line with reports of the increased
cardiovascular risk associated with reducing ABPI.2
Further work is required, however, to demonstrate
the link between platelet activation and adverse cardio-
vascular outcomes in this specific patient group. We are
therefore conducting a trial of dual antiplatelet therapy
(aspirin plus clopidogrel) vs aspirin alone, in patients
undergoing surgery for CLI. The effect of intensive anti-
platelet therapy on platelet markers, cardiac troponin, and
high-selective C-reactive protein will be noted. This may
inform the design of larger-scale clinical trials powered at
Fig 4. Perioperative monocyte activation in patients undergoing
surgery for critical limb ischemia (’) and arthroplasty (●). Mono-
cyte activation in patients undergoing infrainguinal bypass or
amputation was significantly greater than in patients undergoing
arthroplasty throughout the whole perioperative period (P 
.0001). A, Percentage monocyte CD40 expression tended to rise
immediately postoperatively in orthopedic patients before return-
ing to baseline (P .05) B, There was no significant postoperative
change in monocyte CD11b (mean fluorescent intensity) in ar-
throplasty patients (P  .05), but levels appeared to rise on day 1
after surgery in those with critical limb ischemia (P  .05).examining clinical end points in this population.
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